Artal Group S.A. Adaptimmune Therapeutics PLC Transaction History

Artal Group S.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$0.9 - $1.51 $1.02 Million - $1.71 Million	1,133,775 New	1,133,775 $1.05 Million
Q1 2018 May 10, 2018	SELL	$7.1 - $11.56 $4.97 Million - $8.09 Million	-700,000 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$6.68 - $8.74 $1.34 Million - $1.75 Million	200,000 Added 40.0%	700,000 $4.68 Million
Q3 2017 Nov 08, 2017	BUY	$4.93 - $8.93 $2.47 Million - $4.47 Million	500,000	500,000 $4.1 Million

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $96.4M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.